Wedbush Issues Positive Estimate for Disc Medicine Earnings

Disc Medicine, Inc. (NASDAQ:IRON) – Investment analysts at Wedbush raised their FY2028 earnings per share estimates for Disc Medicine in a report issued on Tuesday, January 21st. Wedbush analyst D. Nierengarten now anticipates that the company will post earnings of $7.51 per share for the year, up from their prior estimate of $7.04. Wedbush currently has a “Outperform” rating and a $90.00 price target on the stock. The consensus estimate for Disc Medicine’s current full-year earnings is ($4.07) per share. Wedbush also issued estimates for Disc Medicine’s FY2029 earnings at $12.05 EPS.

Other equities analysts also recently issued research reports about the company. Raymond James raised Disc Medicine from an “outperform” rating to a “strong-buy” rating and boosted their price target for the stock from $66.00 to $110.00 in a research report on Monday, November 4th. Cantor Fitzgerald reissued an “overweight” rating and set a $85.00 price target on shares of Disc Medicine in a research report on Tuesday, October 15th. Morgan Stanley raised Disc Medicine from an “equal weight” rating to an “overweight” rating and set a $85.00 price target on the stock in a research report on Tuesday, November 5th. Scotiabank boosted their price objective on Disc Medicine from $70.00 to $73.00 and gave the stock a “sector outperform” rating in a report on Wednesday. Finally, HC Wainwright restated a “buy” rating and set a $118.00 price objective on shares of Disc Medicine in a report on Tuesday. Nine equities research analysts have rated the stock with a buy rating and one has assigned a strong buy rating to the company. Based on data from MarketBeat, the company presently has a consensus rating of “Buy” and an average target price of $88.50.

Disc Medicine Stock Down 2.6 %

Shares of NASDAQ IRON opened at $56.99 on Wednesday. The business’s 50 day moving average price is $62.66 and its two-hundred day moving average price is $53.72. The company has a market cap of $1.70 billion, a PE ratio of -14.32 and a beta of 0.75. Disc Medicine has a twelve month low of $25.60 and a twelve month high of $77.60.

Disc Medicine (NASDAQ:IRON) last announced its quarterly earnings results on Tuesday, November 12th. The company reported ($0.89) earnings per share for the quarter, topping analysts’ consensus estimates of ($1.04) by $0.15.

Institutional Investors Weigh In On Disc Medicine

Institutional investors and hedge funds have recently added to or reduced their stakes in the business. Amalgamated Bank lifted its stake in Disc Medicine by 76.9% during the second quarter. Amalgamated Bank now owns 568 shares of the company’s stock worth $26,000 after purchasing an additional 247 shares during the last quarter. Mirae Asset Global Investments Co. Ltd. lifted its stake in Disc Medicine by 45.7% during the third quarter. Mirae Asset Global Investments Co. Ltd. now owns 1,075 shares of the company’s stock worth $54,000 after purchasing an additional 337 shares during the last quarter. Quest Partners LLC bought a new stake in Disc Medicine during the third quarter worth $131,000. Quantbot Technologies LP bought a new stake in Disc Medicine during the third quarter worth $146,000. Finally, Intech Investment Management LLC bought a new stake in Disc Medicine during the third quarter worth $228,000. 83.70% of the stock is currently owned by institutional investors.

Insider Activity at Disc Medicine

In related news, insider Rahul Khara sold 7,500 shares of the business’s stock in a transaction that occurred on Thursday, January 2nd. The stock was sold at an average price of $62.75, for a total value of $470,625.00. Following the completion of the sale, the insider now directly owns 14,035 shares in the company, valued at approximately $880,696.25. The trade was a 34.83 % decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is accessible through this link. Also, CEO John D. Quisel sold 12,791 shares of the business’s stock in a transaction that occurred on Monday, December 16th. The shares were sold at an average price of $66.01, for a total value of $844,333.91. Following the completion of the sale, the chief executive officer now owns 72,065 shares of the company’s stock, valued at approximately $4,757,010.65. This trade represents a 15.07 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last ninety days, insiders sold 85,758 shares of company stock worth $5,400,990. Company insiders own 4.24% of the company’s stock.

About Disc Medicine

Disc Medicine, Inc, together with its subsidiaries, a clinical-stage biopharmaceutical company, engages in the discovery, development, and commercialization of novel treatments for patients suffering from serious hematologic diseases in the United States. The company has assembled a portfolio of clinical and preclinical product candidates that aim to modify fundamental biological pathways associated with the formation and function of red blood cells, primarily heme biosynthesis and iron homeostasis.